5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)+/- chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)

S.Gori; A.Sidoni; M.Colozza; M.G.Mameli; D.Fenocchio; E.Minenza; J.Foglietta; L.Stocchi; V.De Angelis; L.Crinò

首页> 外文期刊>European Journal of Cancer Supplements >5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)+/- chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)

【24h】

5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)+/- chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)

机译：5089使用曲妥珠单抗（T）+/-化疗（CT）治疗并通过免疫组织化学（IHC）过表达HER3的HER2阳性（HER2 +）转移性乳腺癌（MBC）患者（pts）的总体生存期缩短

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
S.Gori; A.Sidoni; M.Colozza; M.G.Mameli; D.Fenocchio; E.Minenza; J.Foglietta; L.Stocchi; V.De Angelis; L.Crinò;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 2128 POSTER PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT): correlation with clinical outcome [J] . S.Gori, V.De Angelis, A.Sidoni, European Journal of Cancer Supplements . 2007,第4期

机译：接受曲妥珠单抗（T）±化疗（CT）治疗的HER2阳性（HER2 +）转移性乳腺癌（MBC）患者（pts）的免疫组织化学（IHC）检测2128 POSTER PTEN，EGFR，MAPK和Akt状态
2. 412 POSTER High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) treated with trastuzumab and chemotherapy [J] . European Journal of Cancer Supplements . 2005,第2期

机译：412 POSTER用曲妥珠单抗和化学疗法治疗的HER2过表达转移性乳腺癌（MBC）患者（pts）脑转移的高发生率
3. 490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review [J] . V.Diéras, M.N.Guilhaume, M.Fall, European Journal of Cancer Supplements . 2010,第3期

机译：490用曲妥珠单抗（T）治疗的HER2阳性（HER2 +）转移性乳腺癌患者（MBC）的长期生存和脑转移发生率：基于机构的评价
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment [O] . Y H Park, H A Jung, M K Choi, 2014

机译：HER3表达和PTEN缺失在接受紫杉烷联合曲妥珠单抗治疗的HER2过表达转移性乳腺癌（MBC）患者中的作用
7. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment [O] . Y H Park, H A Jung, M K Choi, 2013

机译：HER3表达和PTEN损失在接受紫杉烷加曲妥珠单抗治疗的HER2过度抑制转移性乳腺癌（MBC）患者中的作用

5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)+/- chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)

著录项

相似文献

相关主题

期刊订阅